First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors

First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors

PIK3CA is a commonly mutated cancer-associated gene, making it an attractive therapeutic target. Here, the authors report the results of a first-in-human phase Ia trial to assess the safety and recommended phase II dose of CYH33, a PI3Kα inhibitor, in patients with advanced solid tumors.

Bibliographic Details
Main Authors: Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu, Hong-Yun Zhao, Yang Zhang, Zhi-Qiang Wang, Miao-Zhen Qiu, Fei Xu, Qiu-Qiong Yu, Yi-Wu Du, Yan-Xia Shi, De-Sheng Wang, Feng-Hua Wang, Rui-Hua Xu
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-34782-9

Internet

https://doi.org/10.1038/s41467-022-34782-9

Similar Items